Sanara Medtech Inc. is a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets. It markets several products for surgical and chronic wound care applications and has multiple products in its pipeline. Its surgical products, CellerateRX Surgical, TEXAGEN, BiFORM, ACTIGEN, ALLOCYTE, ALLOCYTE Plus Advanced Viable Bone Matrix (ALLOCYTE Plus), BIASURGE, FORTIFY TRG Tissue Repair Graft (FORTIFY TRG), and FORTIFY FLOWABLE Extracellular Matrix (FORTIFY FLOWABLE) are used in a range of surgical specialties to help promote patient healing and reduce the risk of complications. CellerateRX Surgical products, TEXAGEN products, FORTIFY TRG and FORTIFY FLOWABLE are used in specialties, including cardiothoracic, colorectal, general surgery, hand, head and neck, high-risk obstetrics and gynecology, Mohs surgery, neurosurgery, and others.
종목 코드 SMTI
회사 이름Sanara Medtech Inc
상장일Apr 07, 1994
CEOMr. Suresh V. (Sam) Muppalla
직원 수141
유형Ordinary Share
회계 연도 종료Apr 07
주소1200 Summit Avenue
도시FORT WORTH
증권 거래소NASDAQ Capital Market Consolidated
국가United States of America
우편 번호76102
전화18175292300
웹사이트https://sanaramedtech.com/
종목 코드 SMTI
상장일Apr 07, 1994
CEOMr. Suresh V. (Sam) Muppalla
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.

데이터 없음